CA2875025C - Tricyclic inhibitors of poly(adp-ribose)polymerase - Google Patents

Tricyclic inhibitors of poly(adp-ribose)polymerase Download PDF

Info

Publication number
CA2875025C
CA2875025C CA2875025A CA2875025A CA2875025C CA 2875025 C CA2875025 C CA 2875025C CA 2875025 A CA2875025 A CA 2875025A CA 2875025 A CA2875025 A CA 2875025A CA 2875025 C CA2875025 C CA 2875025C
Authority
CA
Canada
Prior art keywords
compound
substituted
solvate
pharmaceutically acceptable
unsubstituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2875025A
Other languages
English (en)
French (fr)
Other versions
CA2875025A1 (en
Inventor
Wang Shen
Jack Maung
Aimin Zhang
Xiaoling Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rakovina Therapeutics Inc
Original Assignee
Rakovina Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rakovina Therapeutics Inc filed Critical Rakovina Therapeutics Inc
Publication of CA2875025A1 publication Critical patent/CA2875025A1/en
Application granted granted Critical
Publication of CA2875025C publication Critical patent/CA2875025C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6564—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms
    • C07F9/6581—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms
    • C07F9/6584—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having phosphorus atoms, with or without nitrogen, oxygen, sulfur, selenium or tellurium atoms, as ring hetero atoms having phosphorus and nitrogen atoms with or without oxygen or sulfur atoms, as ring hetero atoms having one phosphorus atom as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2875025A 2011-05-31 2012-05-31 Tricyclic inhibitors of poly(adp-ribose)polymerase Active CA2875025C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161491851P 2011-05-31 2011-05-31
US61/491,851 2011-05-31
PCT/US2012/040304 WO2012166983A1 (en) 2011-05-31 2012-05-31 Tricyclic inhibitors of poly(adp-ribose)polymerase

Publications (2)

Publication Number Publication Date
CA2875025A1 CA2875025A1 (en) 2012-12-06
CA2875025C true CA2875025C (en) 2021-08-03

Family

ID=47259874

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2875025A Active CA2875025C (en) 2011-05-31 2012-05-31 Tricyclic inhibitors of poly(adp-ribose)polymerase

Country Status (8)

Country Link
US (4) US20140221314A1 (https=)
EP (2) EP2714703B1 (https=)
JP (1) JP5960253B2 (https=)
CN (1) CN103717609B (https=)
CA (1) CA2875025C (https=)
ES (1) ES2871052T3 (https=)
TW (1) TWI577693B (https=)
WO (1) WO2012166983A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2714703B1 (en) 2011-05-31 2021-03-10 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase
PL2938598T3 (pl) 2012-12-31 2017-05-31 Cadila Healthcare Limited Podstawione pochodne ftalazyn-1 (2H)-onu jako selektywne inhibitory polimerazy-1 poli(ADP-rybozy)
US10562886B2 (en) 2015-05-21 2020-02-18 The Regents Of The University Of California Anti-cancer compounds
HUE066216T2 (hu) 2016-06-24 2024-07-28 Univ California Ftalazin származékok, mint a parp1, parp2 és/vagy tubulin inhibitorai, hasznosak a rák kezelésében
CA3095709A1 (en) * 2018-04-05 2019-10-10 Noviga Research Ab Novel combinations of a tubulin polymerization inhibitor and a poly (adp-ribose) polymerase (parp) inhibitor for use in the treatment of cancer
EP4013749B1 (en) 2019-08-15 2026-03-11 Black Diamond Therapeutics, Inc. Alkynyl quinazoline compounds
CN112574122B (zh) * 2019-09-27 2024-05-31 上海天慈国际药业有限公司 一种奥拉帕尼关键中间体的制备方法
CN114276301B (zh) * 2020-09-27 2025-04-01 江西科睿药业有限公司 Parp抑制剂的中间体化合物及其制备方法和应用
CN112624981B (zh) * 2021-03-09 2021-05-25 南京桦冠生物技术有限公司 一种2-氟-5-[(4-氧代-3h-2,3-二氮杂萘基)甲基]苯甲酸的制备方法

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1186606T4 (da) 1995-11-17 2011-12-05 Biotechnolog Forschung Gmbh Epothilonderivater, deres fremstilling og anvendelse
WO1999001124A1 (en) 1996-12-03 1999-01-14 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
CN1345334A (zh) 1999-01-29 2002-04-17 伊姆克罗尼系统公司 对kdr特异的抗体及其应用
GB9904387D0 (en) 1999-02-25 1999-04-21 Pharmacia & Upjohn Spa Antitumour synergistic composition
EP1187633A4 (en) 1999-04-08 2005-05-11 Arch Dev Corp USE OF ANTI-VEGF ANTIBODIES TO ENHANCE RADIATION IN ANTICANCER THERAPY
US7151102B2 (en) * 2000-10-30 2006-12-19 Kudos Pharmaceuticals Limited Phthalazinone derivatives
PL223343B1 (pl) 2000-10-30 2016-10-31 Kudos Pharm Ltd Zastosowanie związku, kompozycja farmaceutyczna zawierająca związek oraz pochodne ftalazynonowe
RU2292337C2 (ru) 2002-02-19 2007-01-27 Оно Фармасьютикал Ко., Лтд. Конденсированные производные пиридазина и лекарственные препараты, содержащие данные соединения в качестве активного ингредиента
DE60335359D1 (de) 2002-04-30 2011-01-27 Kudos Pharm Ltd Phthalazinonderivate
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
BRPI0408284B8 (pt) * 2003-03-12 2021-05-25 Kudos Pharm Ltd compostos derivados de ftalazinona, seu uso e composição farmacêutica compreendendo os mesmos
CA2577191A1 (en) * 2004-08-26 2006-03-02 Kudos Pharmaceuticals Limited 4-heteroarylmethyl substituted phthalazinone derivatives
GB0419072D0 (en) * 2004-08-26 2004-09-29 Kudos Pharm Ltd Phthalazinone derivatives
GB0521373D0 (en) 2005-10-20 2005-11-30 Kudos Pharm Ltd Pthalazinone derivatives
GB0610680D0 (en) 2006-05-31 2006-07-12 Istituto Di Ricerche D Biolog Therapeutic compounds
EP2049124A4 (en) 2006-07-20 2010-02-10 Merck & Co Inc PHOSPHOR DERIVATIVES AS HISTONDEACETYLASE HEMMER
DK2120579T3 (da) 2006-12-28 2014-02-03 Abbvie Inc Inhibitorer af poly(ADP-ripose)polymerase
US8466150B2 (en) 2006-12-28 2013-06-18 Abbott Laboratories Inhibitors of poly(ADP-ribose)polymerase
US20080280910A1 (en) 2007-03-22 2008-11-13 Keith Allan Menear Phthalazinone derivatives
TW200900396A (en) 2007-04-10 2009-01-01 Kudos Pharm Ltd Phthalazinone derivatives
US20090023727A1 (en) 2007-07-05 2009-01-22 Muhammad Hashim Javaid Phthalazinone derivatives
MX2010002749A (es) 2007-09-14 2010-06-25 Astrazeneca Ab Derivados de ftalazinona.
CA2702429A1 (en) * 2007-10-17 2009-04-23 Kudos Pharmaceuticals Limited Crystalline form l 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2h-phthalazin-1-one
ES2524787T3 (es) 2007-11-15 2014-12-12 Msd Italia S.R.L. Derivados de piridazinona como inhibidores de PARP
AR070221A1 (es) 2008-01-23 2010-03-25 Astrazeneca Ab Derivados de ftalazinona inhibidores de polimerasas, composiciones farmaceuticas que los contienen y usos de los mismos para prevenir y/o tratar tumores cancerigenos,lesiones isquemicas y otras enfermedades asociadas.
PT2300013T (pt) * 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
CN102459258B (zh) * 2009-06-05 2015-11-25 赛福伦公司 1,2,4-三唑并[1,5a]吡啶衍生物的制备和用途
SG177451A1 (en) 2009-07-02 2012-02-28 Newgen Therapeutics Inc Phosphorus containing quinazoline compounds and methods of use
EP2714703B1 (en) 2011-05-31 2021-03-10 Newgen Therapeutics, Inc. Tricyclic inhibitors of poly(adp-ribose)polymerase

Also Published As

Publication number Publication date
US20230027257A1 (en) 2023-01-26
EP2714703A4 (en) 2014-12-31
US20140221314A1 (en) 2014-08-07
JP2014516989A (ja) 2014-07-17
JP5960253B2 (ja) 2016-08-02
TW201311713A (zh) 2013-03-16
EP2714703B1 (en) 2021-03-10
CN103717609B (zh) 2016-05-11
CN103717609A (zh) 2014-04-09
US20200299315A1 (en) 2020-09-24
EP2714703A1 (en) 2014-04-09
ES2871052T3 (es) 2021-10-28
EP3925962A1 (en) 2021-12-22
US11248013B2 (en) 2022-02-15
US20170057984A1 (en) 2017-03-02
WO2012166983A1 (en) 2012-12-06
US20180094010A1 (en) 2018-04-05
CA2875025A1 (en) 2012-12-06
TWI577693B (zh) 2017-04-11

Similar Documents

Publication Publication Date Title
CA2875025C (en) Tricyclic inhibitors of poly(adp-ribose)polymerase
CA3011189C (en) 5-substituted 2-(morpholin-4-yl)-1,7-naphthyridines
CA2711491C (en) Pharmaceutically acceptable salts of 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide
UA112096C2 (uk) Заміщені триазолопіридини та їх застосування як інгібіторів ttk
CA2732797A1 (en) Dihydropyridophthalazinone inhibitors of poly(adp-ribose)polymerase (parp)
AU2009264273B2 (en) Squaric acid derivatives as inhibitors of the nicotinamide
WO2023174329A1 (en) Heteroaromatic compounds as pkmyt1 inhibitors and use thereof
EP4602049A1 (en) Sos1 inhibitors
BRPI0806245B1 (pt) Compostos de fórmula i e seus usos
JP2017505793A (ja) ｍＩＤＨ１阻害剤としてのベンズイミダゾール−２−アミン
CN102186822A (zh) 新脲和硫脲衍生物
US9884063B2 (en) Amido-substituted azole compounds
WO2015051766A1 (en) Amids substituted indazole derivativees as ploy (adp-ribose) polymerase inhibitors
EP3796975A1 (en) Sulfinylaminobenzamide and sulfonylaminobenzamide derivatives
KR20260019517A (ko) 3,4-디히드로프탈라진-1(2h)-온 유도체, 및 이의 제조 방법 및 이의 용도
JP2025506772A (ja) ポロ様キナーゼ４（ｐｌｋ４）阻害剤、医薬組成物、ならびにそれらを調製する方法、及びそれらの使用方法
TW202043203A (zh) 1,2,4-三-3(2h)-酮化合物
US12612425B2 (en) Tricyclic inhibitors of poly(ADP-ribose)polymerase
WO2022257732A1 (zh) 吡咯并[2,1-f][1,2,4]三嗪类衍生物及其应用
HK40049106A (en) Sulfonylaminobenzamide derivatives
HK40049106B (en) Sulfonylaminobenzamide derivatives
HK1261435A1 (en) Combination of benzimidazole anti-cancer agent and a second anti-cancer agent
HK1236531A1 (en) Benzimidazol-2-amines as midh1 inhibitors
HK1142891B (en) Pyrimidinyl pyridazinone derivates
HK1142891A1 (en) Pyrimidinyl pyridazinone derivates

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180531

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250409

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250409